Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
7.62
-0.42 (-5.22%)
Oct 31, 2024, 4:00 PM EDT - Market closed
Foghorn Therapeutics Revenue
Foghorn Therapeutics had revenue of $6.89M in the quarter ending June 30, 2024, with 23.02% growth. This brings the company's revenue in the last twelve months to $35.19M, up 61.95% year-over-year. In the year 2023, Foghorn Therapeutics had annual revenue of $34.16M with 77.63% growth.
Revenue (ttm)
$35.19M
Revenue Growth
+61.95%
P/S Ratio
10.18
Revenue / Employee
$303,319
Employees
116
Market Cap
421.60M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sonida Senior Living | 244.78M |
Ginkgo Bioworks Holdings | 184.34M |
REGENXBIO | 89.04M |
OmniAb | 21.71M |
MeiraGTx Holdings | 8.12M |
Absci | 3.25M |
FHTX News
- 21 days ago - Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors - GlobeNewsWire
- 4 weeks ago - Foghorn Therapeutics to Participate in the BMO Oncology Summit - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewsWire
- 3 months ago - Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update - GlobeNewsWire
- 5 months ago - Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June - GlobeNewsWire
- 5 months ago - Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline - GlobeNewsWire
- 5 months ago - Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire